payday loans
payday loans
Skip to content

Accueil Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias: the time is now (?)
Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias: the time is now (?) Imprimer Envoyer
Lundi, 14 Août 2017 07:23
imagePurpose of review: Therapeutic advances in the management of idiopathic pulmonary fibrosis (IPF) has led to improved outcomes with the use of the antifibrotic agents pirfenidone and nintedanib, with a number of randomized studies demonstrating benefits in slowing disease progression in IPF. However, treatment of other fibrosing interstitial lung diseases (ILD) remains challenging. Recent findings: Observational and uncontrolled studies investigating pirfenidone and nintedanib in non-IPF ILDs suggest potential benefits, although the data is weak. A number of randomized controlled trials evaluating pirfenidone and nintedanib in a variety of fibrosing ILDs are currently enrolling or planned. Summary: The review will discuss the rationale for use of established antifibrotic drugs approved for IPF for use in non-IPF ILD, describe supportive data from observational studies and ongoing clinical trials.

Author:

Read Full Article
 

find-us-on-facebook-2

United4LungHealth

image001

World Allergy Week 2017 The Agony of Hives

WCOPDday2017



PubMed Logo
Word

 To: 

Langtolang Dictionary

CNP2014Ebook

50x50_firefoxsafari_iconGchrome


Notre site est optimisé pour les Navigateurs suivants : Firefox, Safari et Google Chrome. Cliquez sur l'un des logos ci-dessus pour le télécharger et l'installer gratuitement.

Tabac

Accueil Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias: the time is now (?) Top